Erfurth E M, Bülow B, Mikoczy Z, Svahn-Tapper G, Hagmar L
Department of Internal Medicine, University Hospital, Lund, Sweden.
Clin Endocrinol (Oxf). 2001 Nov;55(5):613-6. doi: 10.1046/j.1365-2265.2001.01385.x.
To assess the incidence of second brain tumours in patients operated and irradiated for pituitary tumours.
The study base consisted of a consecutive series of 325 patients operated and irradiated for pituitary tumours, excluding patients with acromegaly and Cushing's disease. Comparison was made with the general population from the same catchment area as the patients. The follow-up period started in 1958 and on an individual basis patients were followed from the onset of postoperative irradiation until December 1995, or until date of death, emigration or a second brain tumour diagnosis, whichever occurred first.
Three brain tumours (two astrocytomas and one meningioma) were observed, compared with 1-13 expected (standardized incidence ratios (SIR) 2.7; 95% confidence interval (CI) 0.6-7.8).
The present study gives no firm support for an increased incidence of a second brain tumour in patients operated and irradiated for pituitary tumours. A crude meta-analysis of the present and previously published cohort studies of patients with irradiated pituitary tumours gives an SIR of 6.1 (95% CI 3.16-10.69). Thus, the results of the meta-analysis are in favour of an increased risk for second brain tumours. A genetic trait that predisposes to both pituitary tumours and brain tumours is an alternative causal factor. There is no definite proof that cranial irradiation per se is the causal factor. This question cannot be fully answered until sufficient cohort studies of nonirradiated pituitary tumour patients have been carried out.
评估接受垂体瘤手术及放疗的患者发生继发性脑肿瘤的发生率。
研究对象为连续325例接受垂体瘤手术及放疗的患者,不包括肢端肥大症和库欣病患者。与来自同一患者集水区的普通人群进行比较。随访期始于1958年,对患者个体从术后放疗开始直至1995年12月,或直至死亡、移民或诊断出继发性脑肿瘤(以先发生者为准)进行随访。
观察到3例脑肿瘤(2例星形细胞瘤和1例脑膜瘤),预期为1 - 13例(标准化发病比(SIR)2.7;95%置信区间(CI)0.6 - 7.8)。
本研究未有力支持接受垂体瘤手术及放疗的患者继发性脑肿瘤发生率增加。对本研究及先前发表的垂体瘤放疗患者队列研究进行的粗略荟萃分析得出的标准化发病比为6.1(95% CI 3.16 - 10.69)。因此,荟萃分析结果支持继发性脑肿瘤风险增加。垂体瘤和脑肿瘤易患的遗传特征是另一种因果因素。尚无确凿证据表明头颅放疗本身就是因果因素。在对未接受放疗的垂体瘤患者进行足够的队列研究之前,这个问题无法得到充分解答。